SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-020943
Filing Date
2022-08-02
Accepted
2022-08-02 09:43:58
Documents
15
Period of Report
2022-08-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51914
2 ex4-6.htm EX-4.6 211722
3 ex4-7.htm EX-4.7 119969
  Complete submission text file 0001493152-22-020943.txt   676888

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ensc-20220802.xsd EX-101.SCH 3704
5 XBRL DEFINITION FILE ensc-20220802_def.xml EX-101.DEF 26619
6 XBRL LABEL FILE ensc-20220802_lab.xml EX-101.LAB 36693
7 XBRL PRESENTATION FILE ensc-20220802_pre.xml EX-101.PRE 25243
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5520
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

IRS No.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 221127140
SIC: 2834 Pharmaceutical Preparations